What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Heart failure
- Cardiology
John J.V. McMurray mostly deals with Internal medicine, Heart failure, Cardiology, Ejection fraction and Heart disease.
His work in Internal medicine tackles topics such as Endocrinology which are related to areas like Gastroenterology.
His Heart failure research is multidisciplinary, incorporating perspectives in Epidemiology, Diabetes mellitus, Intensive care medicine and Candesartan, Angiotensin II.
His Intensive care medicine research includes themes of MEDLINE and Public health.
His work deals with themes such as Valsartan and Proportional hazards model, which intersect with Cardiology.
The study incorporates disciplines such as Irbesartan, Blood pressure, Spironolactone and Cause of death in addition to Ejection fraction.
His most cited work include:
- 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (9721 citations)
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. (9345 citations)
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (3899 citations)
What are the main themes of his work throughout his whole career to date?
John J.V. McMurray mainly investigates Internal medicine, Heart failure, Cardiology, Ejection fraction and Myocardial infarction.
His studies deal with areas such as Diabetes mellitus and Endocrinology as well as Internal medicine.
His biological study spans a wide range of topics, including Clinical trial, Surgery, Intensive care medicine, Placebo and Heart disease.
His work carried out in the field of Intensive care medicine brings together such families of science as Epidemiology and MEDLINE.
His studies in Cardiology integrate themes in fields like Stroke and Proportional hazards model.
The concepts of his Ejection fraction study are interwoven with issues in Candesartan, Natriuretic peptide, Clinical endpoint and Blood pressure.
He most often published in these fields:
- Internal medicine (78.12%)
- Heart failure (71.15%)
- Cardiology (59.10%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (78.12%)
- Heart failure (71.15%)
- Cardiology (59.10%)
In recent papers he was focusing on the following fields of study:
John J.V. McMurray focuses on Internal medicine, Heart failure, Cardiology, Ejection fraction and Hazard ratio.
His work in Internal medicine addresses issues such as Diabetes mellitus, which are connected to fields such as Kidney disease.
His Heart failure study also includes
- Placebo which connect with Adverse effect,
- Myocardial infarction that connect with fields like Stroke.
John J.V. McMurray has researched Cardiology in several fields, including Neprilysin, Proportional hazards model, Blood pressure and Clinical endpoint.
His Ejection fraction study combines topics in areas such as Omecamtiv mecarbil, Renal function, Eplerenone, Quality of life and Sudden cardiac death.
His Hazard ratio research includes elements of Randomized controlled trial and Cohort.
Between 2017 and 2021, his most popular works were:
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (1150 citations)
- Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. (1007 citations)
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (555 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Heart failure
- Cardiology
His primary areas of investigation include Internal medicine, Heart failure, Cardiology, Ejection fraction and Diabetes mellitus.
His Internal medicine study combines topics from a wide range of disciplines, such as Placebo and Dapagliflozin.
His study focuses on the intersection of Heart failure and fields such as Valsartan with connections in the field of Neprilysin.
His Cardiology research incorporates elements of Candesartan, Interquartile range, Proportional hazards model and Renal function.
He interconnects Quality of life, Diastole and Omecamtiv mecarbil in the investigation of issues within Ejection fraction.
His study in Diabetes mellitus is interdisciplinary in nature, drawing from both Insulin and Kidney disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
